Blood Cancer Journal是一本专注于血液肿瘤领域的国际学术期刊，ISSN号为2044-5385，由Springer Nature出版，出版地为英国，出版周期为月刊。该期刊是开放获取（OA）期刊，被SCI收录，2022年影响因子为12.8，在中科院分区中属于医学1区。其发文特点涵盖白血病、淋巴瘤、多发性骨髓瘤等血液系统恶性肿瘤的基础与临床研究，注重原创性研究和综述。杂志质量较高，审稿严格，但因开放获取模式可能存在一定的出版费用风险，需注意投稿时的经济成本。总体而言，该期刊在血液肿瘤领域具有较高的学术影响力。
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons
2025-05-07T17:47:44Z
Temporal changes in survival among adult patients with chronic myeloid leukemia in the period 1995–2022—a Danish nationwide population-based register study
2025-05-07T17:36:12Z
The ratio of brain to liver glucose activity and disease activity in multiple myeloma
2025-05-07T17:36:14Z
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort
2025-05-07T12:26:15Z
Transposable elements as genome regulators in normal and malignant haematopoiesis
2025-05-06T14:49:33Z
Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024
2025-05-03T04:04:49Z
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma
2025-05-02T11:13:38Z
Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group
2025-05-02T17:29:08Z
Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment
2025-04-29T10:39:45Z
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma
2025-04-29T04:21:23Z
Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis
2025-04-28T15:33:41Z
A 6-tsRNA signature for early detection, treatment response monitoring, and prognosis prediction in diffuse large B cell lymphoma
2025-04-28T14:19:11Z
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
2025-04-24T04:03:15Z
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
2025-04-24T16:06:32Z
Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia
2025-04-24T09:33:00Z
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy
2025-04-23T06:18:35Z
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
2025-04-23T20:21:10Z
Basophilia and eosinophilia in primary myelofibrosis: phenotype, genotype, and prognostic correlates
2025-04-21T13:29:46Z
Risk of lymphoid malignancy associated with cancer predisposition genes
2025-04-19T09:12:11Z
